Literature DB >> 17706954

Cross-talk between aldosterone and angiotensin II in vascular smooth muscle cell senescence.

Li-Juan Min1, Masaki Mogi, Jun Iwanami, Jian-Mei Li, Akiko Sakata, Teppei Fujita, Kana Tsukuda, Masaru Iwai, Masatsugu Horiuchi.   

Abstract

OBJECTIVE: Our aim was to examine the possible cross-talk of angiotensin II (Ang II) and aldosterone (Aldo) in the regulation of vascular cell senescence in cultured vascular smooth muscle cells (VSMC).
METHODS: VSMC were prepared from thoracic aorta of adult male Sprague-Dawley rats. Cellular senescence was evaluated by senescence-associated beta-galactosidase (SA-beta-gal) staining and expression of p21, p53, p16, and p27. Oxidative stress was determined by measuring NADPH oxidase activity and superoxide production. Signal transduction was examined by immunoblot analysis with or without RNA interference methods.
RESULTS: Persistent Ang II (100 nM) stimulation increased SA-beta-gal-stained VSMC and enhanced expression of p21, p53, p16, p27 and Ki-ras2A. These effects of Ang II were markedly inhibited by treatment with a selective AT(1) receptor blocker, valsartan, but partially attenuated by a mineralocorticoid receptor antagonist, spironolactone. The culture medium of VSMC treated with Ang II (100 nM) showed a time-dependent increase in Aldo concentration, which increased senescent VSMC. Antioxidant, N-acetyl-l-cysteine or superoxide dismutase attenuated Ang II- or Aldo-induced VSMC senescence and Ki-ras2A expression. A lower dose combination of Ang II (100 pM) and Aldo (1 pM) significantly enhanced SA-beta-gal-stained VSMC with increases in expression of p21, p53, p16, p27 and Ki-ras2A, oxidative stress, and activity of transcription factors such as NF-kappaB, AP-1, whereas Ang II or Aldo alone at these doses did not affect these parameters. Ki-ras2A-siRNA treatment attenuated senescent VSMC, expression of p21, p53, p16 and p27, oxidative stress induced by Ang II or a lower dose combination of Ang II and Aldo.
CONCLUSION: These results suggest that Ang II and Aldo exert cross-talk in VSMC senescence with involvement of oxidative stress and Ki-ras2A, and could provide a therapeutic benefit for age-related vascular disorders by blockade of both Ang II and Aldo.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17706954     DOI: 10.1016/j.cardiores.2007.07.008

Source DB:  PubMed          Journal:  Cardiovasc Res        ISSN: 0008-6363            Impact factor:   10.787


  31 in total

1.  Aldosterone-receptor antagonism as a potential therapeutic option for atrial fibrillation.

Authors:  Uwe Lendeckel; Dobromir Dobrev; Andreas Goette
Journal:  Br J Pharmacol       Date:  2010-04       Impact factor: 8.739

Review 2.  Stabilization of high-risk plaques.

Authors:  Kohei Takata; Satoshi Imaizumi; Bo Zhang; Shin-Ichiro Miura; Keijiro Saku
Journal:  Cardiovasc Diagn Ther       Date:  2016-08

3.  Aldosterone does not contribute to renal p21 expression during the development of angiotensin II-induced hypertension in mice.

Authors:  Daisuke Nakano; Bai Lei; Kento Kitada; Hirofumi Hitomi; Hiroyuki Kobori; Hirohito Mori; Kazushi Deguchi; Tsutomu Masaki; Tohru Minamino; Akira Nishiyama
Journal:  Am J Hypertens       Date:  2011-11-24       Impact factor: 2.689

Review 4.  Aldosterone: effects on the kidney and cardiovascular system.

Authors:  Marie Briet; Ernesto L Schiffrin
Journal:  Nat Rev Nephrol       Date:  2010-03-16       Impact factor: 28.314

5.  Novel Contributors and Mechanisms of Cellular Senescence in Hypertension-Associated Premature Vascular Aging.

Authors:  Cameron G McCarthy; Camilla F Wenceslau; R Clinton Webb; Bina Joe
Journal:  Am J Hypertens       Date:  2019-07-17       Impact factor: 2.689

6.  PKCδ Mediates Mineralocorticoid Receptor Activation by Angiotensin II to Modulate Smooth Muscle Cell Function.

Authors:  Qing Lu; Ana P Davel; Adam P McGraw; Sitara P Rao; Brenna G Newfell; Iris Z Jaffe
Journal:  Endocrinology       Date:  2019-09-01       Impact factor: 4.736

Review 7.  New insights on signaling cascades induced by cross-talk between angiotensin II and aldosterone.

Authors:  Catherine A Lemarié; Pierre Paradis; Ernesto L Schiffrin
Journal:  J Mol Med (Berl)       Date:  2008-03-27       Impact factor: 4.599

Review 8.  Narrative review: the emerging clinical implications of the role of aldosterone in the metabolic syndrome and resistant hypertension.

Authors:  James R Sowers; Adam Whaley-Connell; Murray Epstein
Journal:  Ann Intern Med       Date:  2009-06-02       Impact factor: 25.391

9.  Aldosterone inhibition and coronary endothelial function in women without obstructive coronary artery disease: an ancillary study of the national heart, lung, and blood institute-sponsored women's ischemia syndrome evaluation.

Authors:  Anthony A Bavry; Eileen M Handberg; Tianyao Huo; Amir Lerman; Arshed A Quyyumi; Chrisandra Shufelt; Barry Sharaf; C Noel Bairey Merz; Rhonda M Cooper-DeHoff; George Sopko; Carl J Pepine
Journal:  Am Heart J       Date:  2014-03-01       Impact factor: 4.749

10.  Local renin-angiotensin system mediates endothelial dilator dysfunction in aging arteries.

Authors:  Sheila Flavahan; Fumin Chang; Nicholas A Flavahan
Journal:  Am J Physiol Heart Circ Physiol       Date:  2016-07-15       Impact factor: 4.733

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.